ABSTRACT
Temafloxacin, trovafloxacin (CP-99,219), grepafloxacin (OPC-17116), and clinafloxacin (AM-1091, CI-960, PD127391) are newer generation fluoroquinolones that share a broad spectrum of antimicrobial activity against Enterobacteriacieae, Gram-positive bacteria (including Streptococcus pneumoniae and Staphylococcus aureus), clinically significant anaerobes, and “atypical” respiratory pathogens. Grepafloxacin and trovafloxacin are generally less active against Pseudomonas spp. than ciprofloxacin, sitafloxacin, and clinafloxacin. These agents were withdrawn from the market (temafloxacin, trovafloxacin, and grepafloxacin) or from pre-marketing development (clinafloxacin) in the 1990s following serious antibiotic-related adverse events that came to light during pre- and post-marketing surveillance.
